Contineum Therapeutics (CTNM 4.48%), a clinical-stage biotechnology company focused on developing treatments for serious diseases such as pulmonary fibrosis, multiple sclerosis, and depression, released its second quarter fiscal 2025 results on August 5, 2025. The most notable news in the earnings release was a wider GAAP net loss per share of $(0.62), missing the estimate of$(0.44). Research and development expenses (GAAP) saw a sharp rise as the company continued to advance its clinical pipeline. Managem ...